KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Assets: 2009-2024

Historic Assets for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $2.1 billion.

  • Halozyme Therapeutics' Assets rose 4.87% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year increase of 4.87%. This contributed to the annual value of $2.1 billion for FY2024, which is 19.05% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Assets is $2.1 billion, which was up 19.05% from $1.7 billion recorded in FY2023.
  • Halozyme Therapeutics' Assets' 5-year high stood at $2.1 billion during FY2024, with a 5-year trough of $579.9 million in FY2020.
  • Moreover, its 3-year median value for Assets was $1.8 billion (2022), whereas its average is $1.9 billion.
  • In the last 5 years, Halozyme Therapeutics' Assets surged by 90.44% in 2021 and then decreased by 5.88% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Assets (Yearly) stood at $579.9 million in 2020, then surged by 90.44% to $1.1 billion in 2021, then surged by 66.74% to $1.8 billion in 2022, then declined by 5.88% to $1.7 billion in 2023, then rose by 19.05% to $2.1 billion in 2024.